<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36323462</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-LoCO): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trial.</ArticleTitle><Pagination><StartPage>e061870</StartPage><MedlinePgn>e061870</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e061870</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2022-061870</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Long COVID-19, where symptoms persist 12 weeks after the initial SARS-CoV-2-infection, is a substantial problem for individuals and society in the surge of the pandemic. Common symptoms are fatigue, postexertional malaise and cognitive dysfunction. There is currently no effective treatment and the underlying mechanisms are unknown, although several hypotheses exist, with chronic inflammation as a common denominator. In prospective studies, hyperbaric oxygen therapy (HBOT) has been suggested to be effective for the treatment of similar syndromes such as chronic fatigue syndrome and fibromyalgia. A case series has suggested positive effects of HBOT in long COVID-19. This randomised, placebo-controlled clinical trial will explore HBOT as a potential treatment for long COVID-19. The primary objective is to evaluate if HBOT improves health-related quality of life (HRQoL) for patients with long COVID-19 compared with placebo/sham. The main secondary objective is to evaluate whether HBOT improves endothelial function, objective physical performance and short-term HRQoL.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">A randomised, placebo-controlled, double-blind, phase II clinical trial in 80 previously healthy subjects debilitated due to long COVID-19, with low HRQoL. Clinical data, HRQoL questionnaires, blood samples, objective tests and activity metre data will be collected at baseline. Subjects will be randomised to a maximum of 10 treatments with hyperbaric oxygen or sham treatment over 6&#x2009;weeks. Assessments for safety and efficacy will be performed at 6, 13, 26 and 52 weeks, with the primary endpoint (physical domains in RAND 36-Item Health Survey) and main secondary endpoints defined at 13 weeks after baseline. Data will be reviewed by an independent data safety monitoring board.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">The trial is approved by the Swedish National Institutional Review Board (2021-02634) and the Swedish Medical Products Agency (5.1-2020-36673). Positive, negative and inconclusive results will be published in peer-reviewed scientific journals with open access.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">NCT04842448.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kjellberg</LastName><ForeName>Anders</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4819-1024</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden anders.kjellberg@ki.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perioperative Medicine and Intensive Care, Medical Unit Intensive Care and Thoracic Surgery, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdel-Halim</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassler</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Unit Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Gharbi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Unit Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Ezerjawi</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Unit Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bostr&#xf6;m</LastName><ForeName>Emil</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Unit Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundberg</LastName><ForeName>Carl Johan</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pernow</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medson</LastName><ForeName>Koshiar</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Imaging and Physiology, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalski</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>EDC Scandinavia, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Wallberg</LastName><ForeName>Kenny A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0003-4378-6181</Identifier><AffiliationInfo><Affiliation>Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Reproductive Medicine, Division of Gynecology and Reproduction, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xiaowei</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-2648-1119</Identifier><AffiliationInfo><Affiliation>Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catrina</LastName><ForeName>Sergiu</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6914-3902</Identifier><AffiliationInfo><Affiliation>Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Diabetes, Academic Specialist Center, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Runold</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine Solna, Respiratory Medicine Unit, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xe5;hlberg</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ME Cardiology, Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruchfeld</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine Solna, Division of Infection Diseases, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nygren-Bonnier</LastName><ForeName>Malin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Women's Health and Allied Health Professionals Theme, Medical Unit Occupational Therapy and Physiotherapy, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindholm</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0840-9244</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Division of Hyperbaric medicine, UCSD, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04842448</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006931" MajorTopicYN="Y">Hyperbaric Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CARDIOLOGY</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IMMUNOLOGY</Keyword><Keyword MajorTopicYN="N">REHABILITATION MEDICINE</Keyword><Keyword MajorTopicYN="N">RESPIRATORY MEDICINE (see Thoracic Medicine)</Keyword><Keyword MajorTopicYN="N">VASCULAR MEDICINE</Keyword></KeywordList><CoiStatement>Competing interests: AK and PL disclose funding from Swedish Heart-Lung Foundation (HLF) and Stockholm Health Council for the present trial. AK disclose funding from Oura Health Oy with complimentary hardware and software for the Oura rings. MS discloses funding from Swedish Research Council and Dysautonomia International during the trial and previously from HLF. MS also disclose consulting fees from the Swedish Agency for Health Technology Assessment of Social Services, speaker honoraria from Orion Pharma, Werfen, and has filed a patent for pharmacological treatment in post-COVID postural orthostatic tachycardia syndrome. JK declares consulting fee for statistical work in this trial. LA-H, AH, SEG, SA-E, EB, CJS, JP, KM, KRW, XZ, SBC, MR, JB and MN-B declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>21</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36323462</ArticleId><ArticleId IdType="pmc">PMC9638753</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2022-061870</ArticleId><ArticleId IdType="pii">bmjopen-2022-061870</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Go&#xeb;rtz YMJ, Van Herck M, Delbressine JM, et al. . Persistent symptoms 3&#x2005;months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 2020;6:00542-2020. 10.1183/23120541.00542-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00542-2020</ArticleId><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer RR, Rock MA, Vasilevsky N, et al. . Characterizing long COVID: deep phenotype of a complex condition. EBioMedicine 2021;74:103722. 10.1016/j.ebiom.2021.103722</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103722</ArticleId><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people, 2021. Available: https://spiral.imperial.ac.uk/handle/10044/1/89844 [Accessed 09 Jan 2022].</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021;38:101019. 10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson M, St&#xe5;hlberg M, Runold M, et al. . Long-Haul Post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience. JACC Case Rep 2021;3:573&#x2013;80. 10.1016/j.jaccas.2021.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaccas.2021.01.009</ArticleId><ArticleId IdType="pmc">PMC7946344</ArticleId><ArticleId IdType="pubmed">33723532</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xe5;hlberg M, Reistam U, Fedorowski A, et al. . Post-COVID-19 tachycardia syndrome: a distinct phenotype of post-acute COVID-19 syndrome. Am J Med 2021;134:1451&#x2013;6. 10.1016/j.amjmed.2021.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2021.07.004</ArticleId><ArticleId IdType="pmc">PMC8356730</ArticleId><ArticleId IdType="pubmed">34390682</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. Lancet Respir Med. In: Nice guideline on long COVID, 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, et al. . A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022;22:e102-e107. 10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W, Hillman T, Playford ED, et al. . Managing the long term effects of covid-19: summary of NICE, sign, and RCGP rapid guideline. BMJ 2021;372:n136. 10.1136/bmj.n136</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraro E, German&#xf2; M, Mollace R, et al. . Hif-1, the Warburg effect, and Macrophage/Microglia polarization potential role in COVID-19 pathogenesis. Oxid Med Cell Longev 2021;2021:1&#x2013;10. 10.1155/2021/8841911</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/8841911</ArticleId><ArticleId IdType="pmc">PMC7987467</ArticleId><ArticleId IdType="pubmed">33815663</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang R, Mamun A, Dominic A, et al. . SARS-CoV-2 mediated endothelial dysfunction: the potential role of chronic oxidative stress. Front Physiol 2020;11:605908. 10.3389/fphys.2020.605908</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2020.605908</ArticleId><ArticleId IdType="pmc">PMC7844210</ArticleId><ArticleId IdType="pubmed">33519510</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahdi A, et al. . Erythrocytes Induce Vascular Dysfunction in COVID-19. In: Institutet K, ed. Basic to translational science. SSRN: JACC, 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8849181</ArticleId><ArticleId IdType="pubmed">35194565</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliaei S, SeyedAlinaghi S, Mehrtak M, et al. . The effects of hyperbaric oxygen therapy (HBOT) on coronavirus disease-2019 (COVID-19): a systematic review. Eur J Med Res 2021;26:96. 10.1186/s40001-021-00570-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-021-00570-2</ArticleId><ArticleId IdType="pmc">PMC8374420</ArticleId><ArticleId IdType="pubmed">34412709</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannellotto M, Duarte M, Keller G, et al. . Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial. Emerg Med J 2022;39:88-93. 10.1136/emermed-2021-211253</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/emermed-2021-211253</ArticleId><ArticleId IdType="pmc">PMC8678559</ArticleId><ArticleId IdType="pubmed">34907003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellberg A, Douglas J, Pawlik MT, et al. . Randomised, controlled, open label, multicentre clinical trial to explore safety and efficacy of hyperbaric oxygen for preventing ICU admission, morbidity and mortality in adult patients with COVID-19. BMJ Open 2021;11:e046738. 10.1136/bmjopen-2020-046738</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-046738</ArticleId><ArticleId IdType="pmc">PMC8260306</ArticleId><ArticleId IdType="pubmed">34226219</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellberg A, De Maio A, Lindholm P. Can hyperbaric oxygen safely serve as an anti-inflammatory treatment for COVID-19? Med Hypotheses 2020;144:110224. and. 10.1016/j.mehy.2020.110224</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110224</ArticleId><ArticleId IdType="pmc">PMC7456590</ArticleId><ArticleId IdType="pubmed">33254531</ArticleId></ArticleIdList></Reference><Reference><Citation>De Maio A, Hightower LE. COVID-19, acute respiratory distress syndrome (ARDS), and hyperbaric oxygen therapy (HBOT): what is the link? Cell Stress Chaperones 2020;25:717&#x2013;20. 10.1007/s12192-020-01121-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-020-01121-0</ArticleId><ArticleId IdType="pmc">PMC7232923</ArticleId><ArticleId IdType="pubmed">32424591</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins T, Gonevski M, Clark C, et al. . Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention. Clin Med 2021;21:e629&#x2013;32. 10.7861/clinmed.2021-0462</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2021-0462</ArticleId><ArticleId IdType="pmc">PMC8806311</ArticleId><ArticleId IdType="pubmed">34862223</ArticleId></ArticleIdList></Reference><Reference><Citation>Oscarsson N, M&#xfc;ller B, Ros&#xe9;n A, et al. . Radiation-Induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2-3 trial. Lancet Oncol 2019;20:1602&#x2013;14. 10.1016/S1470-2045(19)30494-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(19)30494-2</ArticleId><ArticleId IdType="pubmed">31537473</ArticleId></ArticleIdList></Reference><Reference><Citation>Efrati S, Golan H, Bechor Y, et al. . Hyperbaric oxygen therapy can diminish fibromyalgia syndrome--prospective clinical trial. PLoS One 2015;10:e0127012. 10.1371/journal.pone.0127012</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0127012</ArticleId><ArticleId IdType="pmc">PMC4444341</ArticleId><ArticleId IdType="pubmed">26010952</ArticleId></ArticleIdList></Reference><Reference><Citation>Akarsu S, Tekin L, Ay H, et al. . The efficacy of hyperbaric oxygen therapy in the management of chronic fatigue syndrome. Undersea Hyperb Med 2013;40:197&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">23682549</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvert M, Kyte D, Mercieca-Bebber R, et al. . Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA 2018;319:483&#x2013;94. 10.1001/jama.2017.21903</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.21903</ArticleId><ArticleId IdType="pubmed">29411037</ArticleId></ArticleIdList></Reference><Reference><Citation>Orwelius L, Nilsson M, Nilsson E, et al. . The Swedish RAND-36 Health Survey - reliability and responsiveness assessed in patient populations using Svensson&#x2019;s method for paired ordinal data. J Patient Rep Outcomes 2018;2:4. 10.1186/s41687-018-0030-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41687-018-0030-0</ArticleId><ArticleId IdType="pmc">PMC5934928</ArticleId><ArticleId IdType="pubmed">29757320</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardt J, Buchwald D, Wilks D, et al. . Health-Related quality of life in patients with chronic fatigue syndrome: an international study. J Psychosom Res 2001;51:431&#x2013;4. 10.1016/S0022-3999(01)00220-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3999(01)00220-3</ArticleId><ArticleId IdType="pubmed">11516765</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagai K, Song Y, Ling JF, et al. . Sleep disturbances and diminished quality of life in postural tachycardia syndrome. Journal of Clinical Sleep Medicine 2011;07:204&#x2013;10. 10.5664/jcsm.28110</Citation><ArticleIdList><ArticleId IdType="doi">10.5664/jcsm.28110</ArticleId><ArticleId IdType="pmc">PMC3077350</ArticleId><ArticleId IdType="pubmed">21509337</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095&#x2013;108. 10.1097/00005650-199711000-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-199711000-00002</ArticleId><ArticleId IdType="pubmed">9366889</ArticleId></ArticleIdList></Reference><Reference><Citation>Burstr&#xf6;m K, Sun S, Gerdtham U-G, et al. . Swedish experience-based value sets for EQ-5D health states. Qual Life Res 2014;23:431&#x2013;42. 10.1007/s11136-013-0496-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-013-0496-4</ArticleId><ArticleId IdType="pmc">PMC3967073</ArticleId><ArticleId IdType="pubmed">23975375</ArticleId></ArticleIdList></Reference><Reference><Citation>Enright PL. The six-minute walk test. Respir Care 2003;48:783&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12890299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ameloot K, Van De Vijver K, Broch O, et al. . Nexfin noninvasive continuous hemodynamic monitoring: validation against continuous pulse contour and intermittent transpulmonary Thermodilution derived cardiac output in critically ill patients. ScientificWorldJournal 2013;2013:1&#x2013;11. 10.1155/2013/519080</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/519080</ArticleId><ArticleId IdType="pmc">PMC3844244</ArticleId><ArticleId IdType="pubmed">24319373</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamburg NM, Benjamin EJ. Assessment of endothelial function using digital pulse amplitude tonometry. Trends Cardiovasc Med 2009;19:6&#x2013;11. 10.1016/j.tcm.2009.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2009.03.001</ArticleId><ArticleId IdType="pmc">PMC3777618</ArticleId><ArticleId IdType="pubmed">19467447</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander Y, Osto E, Schmidt-Trucks&#xe4;ss A, et al. . Endothelial function in cardiovascular medicine: a consensus paper of the European Society of cardiology working groups on atherosclerosis and vascular biology, aorta and peripheral vascular diseases, coronary pathophysiology and microcirculation, and thrombosis. Cardiovasc Res 2021;117:29&#x2013;42. 10.1093/cvr/cvaa085</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvaa085</ArticleId><ArticleId IdType="pmc">PMC7797212</ArticleId><ArticleId IdType="pubmed">32282914</ArticleId></ArticleIdList></Reference><Reference><Citation>Altini M, Kinnunen H. The promise of sleep: a Multi-Sensor approach for accurate sleep stage detection using the Oura ring. Sensors 2021;21:4302. 10.3390/s21134302</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/s21134302</ArticleId><ArticleId IdType="pmc">PMC8271886</ArticleId><ArticleId IdType="pubmed">34201861</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansdorp CA, van Hulst RA. Double-Blind trials in hyperbaric medicine: a narrative review on past experiences and considerations in designing sham hyperbaric treatment. Clin Trials 2018;15:462&#x2013;76. 10.1177/1740774518776952</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1740774518776952</ArticleId><ArticleId IdType="pmc">PMC6136075</ArticleId><ArticleId IdType="pubmed">29865904</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyboer M, Sharma D, Santiago W, et al. . Hyperbaric oxygen therapy: side effects defined and quantified. Adv Wound Care 2017;6:210&#x2013;24. 10.1089/wound.2016.0718</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/wound.2016.0718</ArticleId><ArticleId IdType="pmc">PMC5467109</ArticleId><ArticleId IdType="pubmed">28616361</ArticleId></ArticleIdList></Reference><Reference><Citation>Redberg RF. Sham controls in medical device trials. N Engl J Med 2014;371:892&#x2013;3. 10.1056/NEJMp1406388</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1406388</ArticleId><ArticleId IdType="pubmed">25184861</ArticleId></ArticleIdList></Reference><Reference><Citation>Samsa G, Edelman D, Rothman ML, et al. . Determining clinically important differences in health status measures: a general approach with illustration to the health Utilities index mark II. Pharmacoeconomics 1999;15:141&#x2013;55. 10.2165/00019053-199915020-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-199915020-00003</ArticleId><ArticleId IdType="pubmed">10351188</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>